Phase I results of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2016
This article has no abstract
Epistemonikos ID: 973c53d9ea41def9d2afeadcf0714669422ba8c1
First added on: Feb 07, 2025